Form 4: TriSalus CEO Szela Boosts Equity Holdings

TriSalus Life Sciences CEO Mary T. Szela increased her beneficial ownership through performance stock units, restricted stock units, and stock options.

Summary

• Mary T. Szela, CEO and President of TriSalus Life Sciences, Inc. (TLSI), reported changes in her beneficial ownership.
• Acquired 125,000 Performance Stock Units (PSUs) on February 13, 2024, contingent on achieving $50 million in revenue over any 12 consecutive months by February 28, 2027.
• Acquired 125,000 Restricted Stock Units (RSUs) on November 24, 2025, which will vest in four equal annual installments commencing on November 24, 2025, subject to continued employment.
• Acquired an additional 300,000 PSUs on November 24, 2025, contingent on achieving $75 million in revenue over any 12 consecutive months by December 31, 2027.
• Acquired 250,000 Employee Stock Options on November 24, 2025, with an exercise price of $5.55, vesting over time starting November 24, 2025, and expiring November 23, 2035.
• Following these transactions, Szela beneficially owns 742,802 shares of common stock and 1,578,182 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing indicates strong alignment between the CEO's compensation and the company's future performance, particularly revenue growth. The significant equity grants, especially performance-based units, suggest confidence in achieving strategic objectives and incentivize long-term value creation.

Positives

• Increased alignment of the CEO's interests with shareholder value through significant equity grants.
• Performance-based awards (PSUs) directly link a substantial portion of compensation to specific revenue growth targets ($50 million and $75 million), incentivizing top-line expansion.
• Long-term vesting schedules for RSUs and stock options encourage sustained commitment and performance from the executive.

Negatives

• The grants do not represent an immediate cash investment by the CEO, as these are equity awards.
• The ultimate value of these awards is contingent on future company performance and stock price, introducing inherent risk for the executive.

Risks

• Failure to achieve the specified revenue targets ($50 million by February 28, 2027, and $75 million by December 31, 2027) would result in the forfeiture of the associated PSUs.
• Continued employment is required for the vesting of RSUs, PSUs, and stock options, posing a risk of forfeiture if employment ceases.
• The value of the stock options is subject to the market price of TriSalus Life Sciences, Inc. common stock, which could decline below the exercise price of $5.55, rendering them worthless.

Future Outlook

The grants of performance stock units tied to specific revenue targets of $50 million by February 28, 2027, and $75 million by December 31, 2027, indicate management's strategic focus on achieving significant top-line growth in the coming years. The long-term vesting of RSUs and stock options also suggests an expectation of sustained value creation and executive commitment.

Industry Context

Executive compensation packages in the life sciences industry frequently include a substantial equity component, often structured with performance-based and time-based vesting. This approach aims to align leadership incentives with long-term shareholder value creation and strategic milestones, such as revenue growth or clinical trial achievements. This filing reflects a standard approach to executive incentives in the sector.

Stakeholder Impact

• Shareholders: Increased alignment of the CEO's interests with shareholder value through performance-based and long-term equity incentives. Potential for enhanced long-term company performance if revenue targets are met.
• Employees: The CEO's commitment to long-term growth and performance may foster a stable and goal-oriented work environment.
• Customers/Suppliers: Indirectly impacted by the company's strategic focus on revenue growth, which could lead to expanded operations or product offerings.

Next Steps

• Achieve $50 million in revenue over any 12 consecutive months by February 28, 2027, for the vesting of 125,000 PSUs.
• Achieve $75 million in revenue over any 12 consecutive months by December 31, 2027, for the vesting of 300,000 PSUs.
• Continued employment through respective vesting dates for RSUs, PSUs, and stock options.
• Vesting of 125,000 RSUs in four equal annual installments commencing November 24, 2025.
• Vesting of 250,000 stock options, with one-fourth vesting on November 24, 2026, and 1/36th of the remaining shares vesting monthly thereafter.

Key Dates

Keywords

TriSalus Life Sciences, TLSI, Mary T. Szela, Performance Stock Units, Restricted Stock Units, Stock Options, Executive Compensation, Insider Transaction, Beneficial Ownership, Revenue Targets